BD PharmingenTM PE Mouse Anti-Pig IFN-gamma

Description

Expression of IFN-gamma by stimulated pig peripheral blood mononuclear cells PBMC . Pig PBMC were stimulated for 20 hours with PMA 5 ng/ml final concentration, Sigma, Cat. No. P-8139 and ionomycin 500 ng/ml final concentration, Sigma, Cat. No. I-0634 in the presence of BD GolgiStop 4 mul/6 ml, Cat. No. 554724. . The PBMC were harvested, fixed, permeabilized, and subsequently stained with 0.015 mug of PE-conjugated mouse anti-porcine IFN-gamma antibody PE-P2G10, Cat. No. 559812 by using the BD Biosciences Pharmingen staining protocol center panel . To demonstrate specificity of staining, the binding by the PE-P2G10 antibody was blocked by pre-incubation of the fixed/permeabilized cells with unlabeled P2G10 antibody 10 mug; Cat. No. 559961; right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the staining profile using 0.12 mug of PE-MOPC-21 isotype control antibody Cat. No. 554680, left panel and verified using the unlabeled antibody blocking specificity control. Expression of IFN-gamma by stimulated pig peripheral blood mononuclear cells PBMC . Pig PBMC were stimulated for 20 hours with PMA 5 ng/ml final concentration, Sigma, Cat. No. P-8139 and ionomycin 500 ng/ml final concentration, Sigma, Cat. No. I-0634 in the presence of BD GolgiStop 4 mul/6 ml, Cat. No. 554724. . The PBMC were harvested, fixed, permeabilized, and subsequently stained with 0.015 mug of PE-conjugated mouse anti-porcine IFN-gamma antibody PE-P2G10, Cat. No. 559812 by using the BD Biosciences Pharmingen staining protocol center panel . To demonstrate specificity of staining, the binding by the PE-P2G10 antibody was blocked by pre-incubation of the fixed/permeabilized cells with unlabeled P2G10 antibody 10 mug; Cat. No. 559961; right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the staining profile using 0.12 mug of PE-MOPC-21 isotype control antibody Cat. No. 554680, left panel and verified using the unlabeled antibody blocking specificity control. Expression of IFN-gamma by stimulated pig peripheral blood mononuclear cells PBMC . Pig PBMC were stimulated for 20 hours with PMA 5 ng/ml final concentration, Sigma, Cat. No. P-8139 and ionomycin 500 ng/ml final concentration, Sigma, Cat. No. I-0634 in the presence of BD GolgiStop 4 mul/6 ml, Cat. No. 554724. . The PBMC were harvested, fixed, permeabilized, and subsequently stained with 0.015 mug of PE-conjugated mouse anti-porcine IFN-gamma antibody PE-P2G10, Cat. No. 559812 by using the BD Biosciences Pharmingen staining protocol center panel . To demonstrate specificity of staining, the binding by the PE-P2G10 antibody was blocked by pre-incubation of the fixed/permeabilized cells with unlabeled P2G10 antibody 10 mug; Cat. No. 559961; right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the staining profile using 0.12 mug of PE-MOPC-21 isotype control antibody Cat. No. 554680, left panel and verified using the unlabeled antibody blocking specificity control. Show More Expression of IFN-gamma by stimulated pig peripheral blood mononuclear cells PBMC . Pig PBMC were stimulated for 20 hours with PMA 5 ng/ml final concentration, Sigma, Cat. No. P-8139 and ionomycin 500 ng/ml final concentration, Sigma, Cat. No. I-0634 in the presence of BD GolgiStop 4 mul/6 ml, Cat. No. 554724. . The PBMC were harvested, fixed, permeabilized, and subsequently stained with 0.015 mug of PE-conjugated mouse anti-porcine IFN-gamma antibody PE-P2G10, Cat. No. 559812 by using the BD Biosciences Pharmingen staining protocol center panel . To demonstrate specificity of staining, the binding by the PE-P2G10 antibody was blocked by pre-incubation of the fixed/permeabilized cells with unlabeled P2G10 antibody 10 mug; Cat. No. 559961; right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the staining profile using 0.12 mug of PE-MOPC-21 isotype control antibody Cat. No. 554680, left panel and verified using the unlabeled antibody blocking specificity control. Show More Expression of IFN-gamma by stimulated pig peripheral blood mononuclear cells PBMC . Pig PBMC were stimulated for 20 hours with PMA 5 ng/ml final concentration, Sigma, Cat. No. P-8139 and ionomycin 500 ng/ml final concentration, Sigma, Cat. No. I-0634 in the presence of BD GolgiStop 4 mul/6 ml, Cat. No. 554724. . The PBMC were harvested, fixed, permeabilized, and subsequently stained with 0.015 mug of PE-conjugated mouse anti-porcine IFN-gamma antibody PE-P2G10, Cat. No. 559812 by using the BD Biosciences Pharmingen staining protocol center panel . To demonstrate specificity of staining, the binding by the PE-P2G10 antibody was blocked by pre-incubation of the fixed/permeabilized cells with unlabeled P2G10 antibody 10 mug; Cat. No. 559961; right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the staining profile using 0.12 mug of PE-MOPC-21 isotype control antibody Cat. No. 554680, left panel and verified using the unlabeled antibody blocking specificity control. Expression of IFN-gamma by stimulated pig peripheral blood mononuclear cells PBMC . Pig PBMC were stimulated for 20 hours with PMA 5 ng/ml final concentration, Sigma, Cat. No. P-8139 and ionomycin 500 ng/ml final concentration, Sigma, Cat. No. I-0634 in the presence of BD GolgiStop 4 mul/6 ml, Cat. No. 554724. . The PBMC were harvested, fixed, permeabilized, and subsequently stained with 0.015 mug of PE-conjugated mouse anti-porcine IFN-gamma antibody PE-P2G10, Cat. No. 559812 by using the BD Biosciences Pharmingen staining protocol center panel . To demonstrate specificity of staining, the binding by the PE-P2G10 antibody was blocked by pre-incubation of the fixed/permeabilized cells with unlabeled P2G10 antibody 10 mug; Cat. No. 559961; right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the staining profile using 0.12 mug of PE-MOPC-21 isotype control antibody Cat. No. 554680, left panel and verified using the unlabeled antibody blocking specificity control.